Scope Fluidics Spolka Akcyjna (FRA:S84) EBIT: €-10.89 Mil (TTM As of Mar. 2026)


FRA:S84 Scope Fluidics Spolka Akcyjna FRA:S84
44 GF Score
Price €23.70
GF Value €26.28
! 4 Warning Signs
View Full Analysis

What is Scope Fluidics Spolka Akcyjna EBIT?

Scope Fluidics Spolka Akcyjna FRA:S84 +0.64% 44 EBIT is €-10.89 Mil as of Mar. 2026. GuruFocus rates FRA:S84 with a GF Score™ of 44/100 and a GF Value™ of €26.28. The stock has 4 warning signs investors should review.

Scope Fluidics Spolka Akcyjna's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-3.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-10.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scope Fluidics Spolka Akcyjna's annualized ROC % for the quarter that ended in Mar. 2026 was -157.99%. Scope Fluidics Spolka Akcyjna's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -468.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Scope Fluidics Spolka Akcyjna's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -19.55%.


Scope Fluidics Spolka Akcyjna  (FRA:S84) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scope Fluidics Spolka Akcyjna's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-13.54 * ( 1 - 0% )/( (8.416 + 8.724)/ 2 )
=-13.54/8.57
=-157.99 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Scope Fluidics Spolka Akcyjna's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.424/( ( (2.48 + max(-1.306, 0)) + (2.82 + max(-0.88199999999999, 0)) )/ 2 )
=-12.424/( ( 2.48 + 2.82 )/ 2 )
=-12.424/2.65
=-468.83 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.381 + 0) - (1.373 + 0 + 1.314)
=-1.306

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.733 + 7.105427357601E-15) - (1.582 + 0 + 1.033)
=-0.88199999999999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scope Fluidics Spolka Akcyjna's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-10.893/55.719
=-19.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scope Fluidics Spolka Akcyjna EBIT Related Terms


Scope Fluidics Spolka Akcyjna EBIT Historical Data

* Premium members only.

The historical data trend for Scope Fluidics Spolka Akcyjna's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scope Fluidics Spolka Akcyjna EBIT Chart

Scope Fluidics Spolka Akcyjna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.42 92.21 -4.28 19.94 -10.68

Scope Fluidics Spolka Akcyjna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -1.61 -2.61 -3.57 -3.11

FRA:S84 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scope Fluidics Spolka Akcyjna EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scope Fluidics Spolka Akcyjna's EV-to-EBIT falls into.


FRA:S84
44GF Score
Scope Fluidics Spolka Akcyjna FRA:S84
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scope Fluidics Spolka Akcyjna EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-10.89 Mil mean?
Scope Fluidics Spolka Akcyjna (FRA:S84) has a EBIT of €-10.89 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scope Fluidics Spolka Akcyjna.
Is Scope Fluidics Spolka Akcyjna's EBIT too high?
Scope Fluidics Spolka Akcyjna's current EBIT is €-10.89 Mil. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's EBIT compare to TMO and DHR?
Scope Fluidics Spolka Akcyjna's EBIT of €-10.89 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scope Fluidics Spolka Akcyjna. Scope Fluidics Spolka Akcyjna's current EBIT is €-10.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Scope Fluidics Spolka Akcyjna (FRA:S84) has a current EBIT of €-10.89 Mil. The stock's GF Value™ is €26.28, compared to a current price of €23.70 — trading 9.8% below its estimated fair value. The current EBIT is €-10.89 Mil. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (FRA:S84), the current EBIT is €-10.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scope Fluidics Spolka Akcyjna (FRA:S84) Overvalued in 2026?

Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued. The current stock price of €23.70 is trading 9.8% below its estimated GF Value™ of €26.28.

Key valuation signals for FRA:S84:

  • EBIT: €-10.89 Mil
  • GF Value™: €26.28 vs. price of €23.70 (9.8% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the FRA:S84 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scope Fluidics Spolka Akcyjna Business Description

Other Exchanges SCP:Poland
Address Duchnicka 3, Build 16, Entrance A, Warsaw, POL, 01-796
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
44GF Score

Get the complete analysis for FRA:S84

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.70
Price
€26.28
GF Value